Cluster of Differentiation 44 Targeted Hyaluronic Acid Based Nanoparticles for MDR1 siRNA Delivery to Overcome Drug Resistance in Ovarian Cancer.
about
Cosilencing of PKM-2 and MDR-1 Sensitizes Multidrug-Resistant Ovarian Cancer Cells to Paclitaxel in a Murine Model of Ovarian CancerHyaluronic acid reagent functional chitosan-PEI conjugate with AQP2-siRNA suppressed endometriotic lesion formationMicroRNA-223 Induced Repolarization of Peritoneal Macrophages Using CD44 Targeting Hyaluronic Acid Nanoparticles for Anti-Inflammatory EffectsProteomic characterization of circulating extracellular vesicles identifies novel serum myeloma associated markersPancreatic Cancer Cell Exosome-Mediated Macrophage Reprogramming and the Role of MicroRNAs 155 and 125b2 Transfection using Nanoparticle Delivery SystemsThe Role of CD44 in Disease Pathophysiology and Targeted Treatment.Recent advances in hyaluronic acid-decorated nanocarriers for targeted cancer therapy.Nanotechnology in Glycomics: Applications in Diagnostics, Therapy, Imaging, and Separation Processes.Gene Therapeutic Approaches to Overcome ABCB1-Mediated Drug Resistance.Paclitaxel and Its Evolving Role in the Management of Ovarian Cancer.Modulation of Macrophage Functional Polarity towards Anti-Inflammatory Phenotype with Plasmid DNA Delivery in CD44 Targeting Hyaluronic Acid Nanoparticles.Emerging Therapeutics to Overcome Chemoresistance in Epithelial Ovarian Cancer: A Mini-Review.Targeted Delivery of siRNA Therapeutics to Malignant Tumors.Copper-Free 'Click' Chemistry-Based Synthesis and Characterization of Carbonic Anhydrase-IX Anchored Albumin-Paclitaxel Nanoparticles for Targeting Tumor Hypoxia.Inhibition of CDK4 sensitizes multidrug resistant ovarian cancer cells to paclitaxel by increasing apoptosiss.Bacterial polymers as materials for the development of micro/nanoparticles
P2860
Q35836455-22D5947C-0CA0-4349-9B9F-AC3C787DCDFDQ35995453-BDD787E2-9C75-453F-A298-8AB77CDD0D0DQ36009269-825FF669-3776-4092-92A2-1D23E1F0A0C9Q36665156-2E7153DD-865A-4B7A-AA78-999C73A8708CQ37117425-403439EE-3353-415B-BDAF-0D0DB2F2DA6BQ38466771-8870AA76-C3CC-4239-B7EF-FF7C07C5378EQ38778198-CCED59F7-6B50-4B19-ACAF-B82850C22C0CQ39012279-0DC37245-9300-4439-AA80-F447E16BCD3FQ39094446-2AD71A25-46B3-4BCF-8BCD-5B98D4F4BC5AQ41897007-97F19510-74F2-4893-B639-AC2AF4D782DAQ43168468-B4F6BF56-8341-40A1-81FF-80DA948D1774Q45070718-0A43E9E0-E575-4C39-A1D4-456D65F1065BQ47152520-1DDED840-EE57-442A-B104-4938E2A35175Q52658028-575E0BC3-0CE6-4A55-A5C6-5753FA193A85Q53749392-CDEA35D0-2164-4500-9464-7ACC155C29FAQ58461450-C32E5742-363D-4CE7-9A28-25795F88F05A
P2860
Cluster of Differentiation 44 Targeted Hyaluronic Acid Based Nanoparticles for MDR1 siRNA Delivery to Overcome Drug Resistance in Ovarian Cancer.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Cluster of Differentiation 44 ...... Resistance in Ovarian Cancer.
@ast
Cluster of Differentiation 44 ...... Resistance in Ovarian Cancer.
@en
type
label
Cluster of Differentiation 44 ...... Resistance in Ovarian Cancer.
@ast
Cluster of Differentiation 44 ...... Resistance in Ovarian Cancer.
@en
prefLabel
Cluster of Differentiation 44 ...... Resistance in Ovarian Cancer.
@ast
Cluster of Differentiation 44 ...... Resistance in Ovarian Cancer.
@en
P2093
P2860
P1476
Cluster of Differentiation 44 ...... Resistance in Ovarian Cancer.
@en
P2093
Amit Singh
Edwin Choy
Francis J Hornicek
Lara Milane
Mansoor M Amiji
Xiaoqian Yang
Zhenfeng Duan
P2860
P304
P356
10.1007/S11095-014-1602-1
P50
P577
2014-12-17T00:00:00Z